A computational drug discovery engine that transforms clinically validated natural product scaffolds into patent-protected drug candidates — targeting orphan diseases and companion animal health at a fraction of conventional cost and timeline.
Most drug discovery starts from blank chemistry. We don't. Our starting compounds come from pharmacopoeias with decades to centuries of documented clinical use — with published pharmacokinetic data, known safety profiles, and real biological signals. This dramatically reduces translational risk.
The platform models how each molecule binds at residue-level resolution, then uses that structural feedback to guide molecular modifications — fluoroalkyl metabolic armor, aromatic ether binding enhancement, and calibrated ADMET prediction with literature-anchored domain shift correction.
Every computational prediction is held accountable to wet-lab reality. Lead compounds are synthesized and validated through binding assays with international CROs. Each round of experimental data improves predictions across the entire compound matrix — a self-improving computational flywheel.
| Panel | Targets | Focus |
|---|---|---|
| CNS | 256 | Epilepsy, ALS, neurodegeneration, behavioral disorders |
| Human Safety | 44 | Standard 44-target off-target safety panel |
| Companion Animal Safety | 28 | Species-specific veterinary safety |
| Dermatology | 50 | Atopic dermatitis, immune-mediated skin conditions |
| Oncology | 19 | Drug-resistant hematologic malignancy (AML) |
Multi-target compound designed for companion animal behavioral disorders. Synthesis complete via international CRO. Binding assay panel in progress. Results expected Q2 2026.
Dual-target candidate with computationally predicted activity against drug-resistant pathways. Awaiting lead program results before synthesis commitment.
Multiple candidates across rare pediatric epilepsy (DEE, Dravet Syndrome), ALS, translational dermatology, and additional orphan indications.
7+ US provisional patents protect our drug assets and the computational methods used to create them — including novel compound families, multi-target interaction prediction methodology, and indication-specific therapeutic claims across multiple independent scaffolds.
We offer patent-protected drug assets ready for licensing, co-development, or regional partnership — across orphan CNS, pediatric neurology, oncology, and companion animal health.
Pipeline assets available for licensing in both human orphan disease and companion animal health indications.